Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis, PMID: 32207094
[Certolizumab], PMID: 31208736
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT), PMID: 29660425
Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis, PMID: 31917928
Certolizumab pegol, PMID: 20190560
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation, PMID: 27140438
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2), PMID: 29660421
Certolizumab pegol for hidradenitis suppurativa: Case report and literature review, PMID: 33135826
Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database, PMID: 29623679
Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study, PMID: 29030361
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis, PMID: 30848558
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction, PMID: 32381562
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials, PMID: 31245056
Certolizumab pegol for the treatment of psoriasis, PMID: 28165828
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis, PMID: 30943133
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2), PMID: 32652544
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics, PMID: 30772098
Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases, PMID: 27704400
Certolizumab for rheumatoid arthritis, PMID: 24447441
Long-term efficacy of certolizumab pegol for psoriasis, PMID: 32951203
Certolizumab pegol for treating axial spondyloarthritis, PMID: 27366922
Certolizumab pegol-induced palmoplantar pustulosis: A case report and review of the literature, PMID: 29370988
Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy, PMID: 33124565
ACG Clinical Guideline: Management of Crohn's Disease in Adults, PMID: 29610508
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA, PMID: 28498975
Certolizumab Pegol-Induced Heart Failure, PMID: 29232326
Certolizumab-induced facial eruption in a pregnant woman with severe Behcet's disease, PMID: 32770724
Certolizumab pegol: in rheumatoid arthritis, PMID: 19894782
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults, PMID: 21328299
Certolizumab pegol: a review of its use in the management of rheumatoid arthritis, PMID: 23338540
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults, PMID: 28884785
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study, PMID: 27863807
Improvement of Certolizumab Fab' properties by PASylation technology, PMID: 33116155
Certolizumab pegol for the treatment of psoriatic arthritis, PMID: 25651776
[Certolizumab pegol], PMID: 21794764
Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis, PMID: 24919863
Certolizumab pegol in axial spondyloarthritis, PMID: 24215406
Certolizumab pegol in Crohn's disease, PMID: 19180261
Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease, PMID: 20118143
Certolizumab pegol: in Crohn's disease, PMID: 17516714
The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation, PMID: 31498069
Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy, PMID: 33247833
Certolizumab pegol for the management of Crohn's disease in adults, PMID: 19695385
Certolizumab pegol for induction of remission in Crohn's disease, PMID: 31476018
Certolizumab pegol in the treatment of Crohn's disease, PMID: 23451881
Certolizumab pegol, PMID: 18670430
Patient Satisfaction with CIMZIA ® (Certolizumab Pegol) AutoClicks ® in the UK, PMID: 32124272
Profile of certolizumab and its potential in the treatment of psoriatic arthritis, PMID: 23620660
Certolizumab pegol: a new biologic targeting rheumatoid arthritis, PMID: 20979550
Certolizumab pegol in the treatment of Takayasu arteritis, PMID: 30010945
Influence of Pharmacokinetic-Pharmacodynamic Failure Mechanisms on Outcomes in Biologic Therapy Sequencing in Inflammatory Bowel Disease: A Retrospective Cohort Study., PMID:40531271
Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial., PMID:40483169
Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial., PMID:40480650
Gender perspective in the management of psoriasis., PMID:40470625
Pharmacogenomics of TNF inhibitors., PMID:40469293
Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation., PMID:40428231
Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry., PMID:40387427
A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment., PMID:40383754
Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis., PMID:40377857
Cardiovascular Outcomes of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Review of the Current Evidence., PMID:40376321
Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance study., PMID:40371340
Real-World Insights From Türkiye: Biologic DMARDs Usage in Spondyloarthritis Patients With Chronic Kidney Disease., PMID:40358366
Aggregate Distributional Cost-Effectiveness Analysis of Biologics for the Treatment of Ankylosing Spondylitis in Chile., PMID:40329067
Novel Small-Molecule Treatment and Emerging Biological Therapy for Psoriasis., PMID:40299379
Racial Disparities in Utilization of Medications and Disease Outcomes in Inflammatory Bowel Disease Patients., PMID:40260307
Transitional and CD21- PD-1+ B cells are associated with remission in early rheumatoid arthritis., PMID:40259340
Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review., PMID:40256995
Triple biologic therapy for refractory Crohn's disease., PMID:40251965
A Case of Rectus Sheath Hematoma Caused by Self-Injection of Certolizumab Pegol., PMID:40196069
Discontinuation vs. continuation of concomitant methotrexate in patients with rheumatoid arthritis on certolizumab pegol: results from a randomised, controlled trial., PMID:40188084
Infection toxicity assessment of tumor necrosis factor α inhibitors in the treatment of IBD: a real-world study based on the US food and drug administration adverse events reporting system (FAERS)., PMID:40156444
Certolizumab-Induced Urticarial Vasculitis: A Case Report., PMID:40143392
Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis., PMID:40136396
Pharmacovigilance study and genetic target prediction analysis of FDA adverse event reports (FAERS) for drug-induced sinusitis., PMID:40128146
Real-Life Analysis of Therapeutic Management and Its Correlation with the Dermatology Life Quality Index Score in 108 Patients with Pustular Psoriasis: An Italian Monocenter Study., PMID:40117644
Cost-effectiveness analysis of subcutaneous biosimilar tocilizumab in patients with rheumatoid arthritis in Spain., PMID:40113553
Rheumatoid Factor Predicts Long-Term Retention Associated With Effectiveness of Certolizumab Pegol in Patients With Rheumatoid Arthritis: A Two-Center Retrospective Study., PMID:40099319
Anti-Rheumatic potential of biological DMARDS and protagonistic role of bio-markers in early detection and management of rheumatoid arthritis., PMID:40091354
Certolizumab enhances spinal cord injury recovery in rats through inhibition of the TNF-α signaling pathway and neuronal apoptosis., PMID:40009347
Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database., PMID:40000785
Rheumatoid factors revisited in the age of biologic therapy., PMID:39982406
Risankizumab and Certolizumab Pegol Dual-Targeted Therapy for Crohn's Disease and Axial Spondyloarthritis: A Case Report., PMID:39981170
The use of aptamers as therapeutic inhibitors and biosensors of TNF-alpha., PMID:39971069
Tumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis., PMID:39941759
Systematic review and bayesian network meta-analysis: comparative efficacy and safety of six commonly used biologic therapies for moderate-to-severe Crohn's disease., PMID:39911832
Certolizumab Pegol Treatment in Patients With Crohn's Disease: Final Safety Data From the SECURE Registry., PMID:39895830
Hidradenitis Suppurativa Treatment During Pregnancy and Lactation: Navigating Challenges., PMID:39887706
Management of Anal Fistula with Crohn's Disease., PMID:39882221
Exploring the neuroprotective potential of immunosuppressants in Parkinson's disease., PMID:39874798
Pharmacovigilance Pregnancy Data in a Population of Japanese Patients With Chronic Inflammatory Disease Exposed to Certolizumab Pegol., PMID:39812078
Certolizumab pegol in severe hidradenitis suppurativa in pregnancy: A case report., PMID:39803378
What is rheumatoid factor? From screening to personalized management., PMID:39792161
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis., PMID:39757285
Effects of Ab501 (certolizumab mice equivalent) in arthritis induced bone loss., PMID:39754728
Impaired coagulation parameters in early RA are restored by effective antirheumatic therapy: a prospective pilot study., PMID:39740931
Effectiveness and Treatment Persistence of Vedolizumab Compared to Anti-Tumour Necrosis Factor-α in Patients With Crohn's Disease: A Systematic Literature Review and Meta-Analysis., PMID:39707930
Certolizumab pegol for plaque psoriasis in women of childbearing potential, pregnant or breastfeeding in clinical settings: One-year outcomes from the international noninterventional CIMREAL study., PMID:39699934
Pulmonary toxicity assessment of tumor necrosis factor α inhibitors in the treatment of IBD: a real world study based on US food and drug administration adverse events reporting system (FAERS)., PMID:39695351
Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet's Disease., PMID:39685848
For research use only. Not for human or drug use.
